Special Issue "Recent Effective Application of Bioisosterism"
Deadline for manuscript submissions: 31 October 2020.
Interests: Bioisosterism; hydroxyazoles; hit to lead; drug design; DHODH inhibitors; leukaemia; prostate cancer; GABAerigic and glutaminergic neurotransmissions
Interests: drug discovery; synthesis and structure–-activity relationships of bioactive compounds; anticancer agents; cancer metabolism; medicinal chemistry; enzymatic assays
Since the introduction of the term “bioisostere” in 1950 by Harris Friedman, the application of bioisosterism has become a fundamental tactical approach in the contemporary practice of medicinal chemistry. During hit-to-lead processes, bioisosterism is often the winning approach to improve potency and selectivity, achieve optimal ADME-T profiles, and acquire novel intellectual properties. In some instances, the eternal confrontation between the definitions of Isostere and Bioisostere well represents the real soul of a medicinal chemist. Isosteres represent the connection with chemistry, being groups describable by chemico-physical parameters. On the contrary, the possibility of applying the bioisosteric definition to an isostere will depend on the biological context, an often brutal remind of how difficult the translation of a chemistry-based design into a living organism activity can be. Since a bioisostere found to be effective for a biochemical application cannot be translated to another setting, the effective application of a bioisosteric approach needs a continuous refinement of its isosteric counterpart, sharpening the tool by introducing structural changes in size, shape, electronic distribution, polarizability, dipole, polarity, lipophilicity (logP), and pKa. All these variables can potentially play a role, in a beneficial or deleterious way, in effectively reaching a bioisosteric definition.
Authors are invited to submit original and review articles describing basic science, preclinical, and clinical findings, that contribute to the understanding of the current and future potential applications of bioisosterism, to be published in this Special Issue of Pharmaceuticals.
Dr. Marco L. Lolli
Dr. Carlotta Granchi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Scaffold hopping
- Drug design
- Hit to lead
- Chemico-physical descriptors
- Structure-based design